The Pharma Letter

October 1, 2025

Crystalys launches with $205M Series A financing

read more →

Pharmaphorum

October 1, 2025

Crystalys emerges with $205m, and other biofinancings

read more →

BioWorld

October 1, 2025

Financings for Oct. 1, 2025

read more →

Axios

September 30, 2025

Pro Rata Premium: First Look

read more →

FirstWord Pharma

September 30, 2025

Crystalys makes its debut with $205M to advance next-gen gout drug

read more →

Biopharma Dive

September 30, 2025

Crystalys debuts with $205M and plans for a better gout drug

read more →

Fierce Biotech

September 30, 2025

James Mackay is tending to ‘unfinished business’ with new gout biotech and $205M fundraise

read more →

BioSpace

September 30, 2025

Novo-Backed Crystalys Debuts With $205M to Tackle Gout

read more →

Reuters

September 30, 2025

Crystalys Therapeutics launches with $205 million funding round for trials of gout drug

read more →

Endpoints News

September 30, 2025

Crystalys lands $205M to bring gout drug first marketed in Japan to the US and Europe

read more →

STAT News

September 30, 2025

Trump’s MFN deadline came and went

read more →